Sleep & longevity research peptides
Sleep and longevity research covers three compounds with very different evidence. DSIP is a nonapeptide isolated in 1977 and named for delta sleep; no receptor for it has been identified, and human sleep studies gave mixed results. Epitalon, the tetrapeptide AEDG, is studied for melatonin synthesis and telomerase, mostly in cells and animals. NAD+ is a coenzyme whose levels fall with age.
How these compare
FAQ
What is DSIP?
DSIP, delta sleep-inducing peptide, is the nonapeptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, isolated from rabbit blood in 1977. No DSIP gene, precursor or receptor has been found. Human studies from the 1980s and 1990s, in chronic insomnia and healthy volunteers, gave mixed sleep results.
What is Epitalon?
Epitalon, also written Epithalon, is the synthetic tetrapeptide Ala-Glu-Asp-Gly, designed from epithalamin, a bovine pineal extract. It is described as acting on melatonin synthesis, gene expression and the enzyme telomerase. Most of the literature is cell and animal work, much of it from one Russian group led by Khavinson.
How strong is the evidence in this area?
Weaker than in most areas. A 2006 review called the case for DSIP as a sleep factor poorly documented, and the few human Epitalon reports give little detail on study size or dose. NAD+ has more human trials, but most gave oral precursors such as NR or NMN rather than NAD+ itself.
Are DSIP and Epitalon legal in Australia?
DSIP and Epitalon are not registered on the ARTG, and NAD+ in this form is not either; there is no TGA-approved product for any of the three. We supply them for laboratory research only, not for human use.